Lingua Marcello Francesco, Carrà Giovanna, Maffeo Beatrice, Morotti Alessandro
Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.
Pharmaceuticals (Basel). 2021 Feb 21;14(2):168. doi: 10.3390/ph14020168.
For many years in the field of onco-hematology much attention has been given to mutations in protein-coding genes or to genetic alterations, including large chromosomal losses or rearrangements. Despite this, biological and clinical needs in this sector remain unmet. Therefore, it is not surprising that recent studies have shifted from coded to non-coded matter. The discovery of non-coding RNAs (ncRNAs) has influenced several aspects related to the treatment of cancer. In particular, in chronic lymphocytic leukemia (CLL) the knowledge of ncRNAs and their contextualization have led to the identification of new biomarkers used to follow the course of the disease, to the anticipation of mechanisms that support resistance and relapse, and to the selection of novel targeted treatment regimens. In this review, we will summarize the main ncRNAs discovered in CLL and the molecular mechanisms by which they are affected and how they influence the development and the progression of the disease.
多年来,肿瘤血液学领域一直高度关注蛋白质编码基因的突变或基因改变,包括大片段染色体缺失或重排。尽管如此,该领域的生物学和临床需求仍未得到满足。因此,近期研究从编码物质转向非编码物质也就不足为奇了。非编码RNA(ncRNA)的发现影响了癌症治疗的多个方面。特别是在慢性淋巴细胞白血病(CLL)中,对ncRNA及其背景的了解已促成了新生物标志物的鉴定,这些生物标志物可用于跟踪疾病进程、预测支持耐药性和复发的机制以及选择新的靶向治疗方案。在本综述中,我们将总结在CLL中发现的主要ncRNA及其受影响的分子机制,以及它们如何影响疾病的发展和进展。